Literature DB >> 28731260

Transcriptional regulation of APP by apoE: To boldly go where no isoform has gone before: ApoE, APP transcription and AD: Hypothesised mechanisms and existing knowledge gaps.

Liying Corinne Lee1, Michele Q L Goh2, Edward H Koo2,3.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia that gradually disrupts the brain network to impair memory, language and cognition. While the amyloid hypothesis remains the leading proposed mechanism to explain AD pathophysiology, anti-amyloid therapeutic strategies have yet to translate into useful therapies, suggesting that amyloid β-protein and its precursor, the amyloid precursor protein (APP) are but a part of the disease cascade. Further, risk of AD can be modulated by a number of factors, the most impactful being the ɛ4 isoform of apolipoprotein E (apoE). A recent study reported a novel isoform-dependent transcriptional regulation of APP by apoE. These interesting new results add to the myriad of mechanisms that have been proposed to explain how apoE4 enhances AD risk, highlighting the complexities of not only apoE and AD pathophysiology, but also of disease itself. Also see the video abstract here: https://youtu.be/yd14MBdPkCY.
© 2017 WILEY Periodicals, Inc.

Entities:  

Keywords:  APP; Alzheimer's disease; ApoE; Aβ; transcription

Mesh:

Substances:

Year:  2017        PMID: 28731260      PMCID: PMC5647194          DOI: 10.1002/bies.201700062

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  84 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

3.  Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms.

Authors:  K H Weisgraber; S C Rall; R W Mahley
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

4.  The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice.

Authors:  John D Fryer; Ronald B Demattos; Lynn M McCormick; Mark A O'Dell; Michael L Spinner; Kelly R Bales; Steven M Paul; Patrick M Sullivan; Maia Parsadanian; Guojun Bu; David M Holtzman
Journal:  J Biol Chem       Date:  2005-05-11       Impact factor: 5.157

5.  Degradation of amylin by insulin-degrading enzyme.

Authors:  R G Bennett; W C Duckworth; F G Hamel
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

Review 6.  Clearance systems in the brain-implications for Alzheimer disease.

Authors:  Jenna M Tarasoff-Conway; Roxana O Carare; Ricardo S Osorio; Lidia Glodzik; Tracy Butler; Els Fieremans; Leon Axel; Henry Rusinek; Charles Nicholson; Berislav V Zlokovic; Blas Frangione; Kaj Blennow; Joël Ménard; Henrik Zetterberg; Thomas Wisniewski; Mony J de Leon
Journal:  Nat Rev Neurol       Date:  2015-07-21       Impact factor: 42.937

7.  Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein.

Authors:  R C Kowal; J Herz; K H Weisgraber; R W Mahley; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

8.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

9.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

Review 10.  The amyloid hypothesis of Alzheimer's disease at 25 years.

Authors:  Dennis J Selkoe; John Hardy
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

View more
  3 in total

Review 1.  The role of innate immunity in Alzheimer's disease.

Authors:  Hannah E Ennerfelt; John R Lukens
Journal:  Immunol Rev       Date:  2020-06-26       Impact factor: 12.988

2.  Comparative Gene-Expression Analysis of Alzheimer's Disease Progression with Aging in Transgenic Mouse Model.

Authors:  Noman Bin Abid; Muhammad Imran Naseer; Myeong Ok Kim
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

3.  APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease.

Authors:  Elles Konijnenberg; Betty M Tijms; Johan Gobom; Valerija Dobricic; Isabelle Bos; Stephanie Vos; Magda Tsolaki; Frans Verhey; Julius Popp; Pablo Martinez-Lage; Rik Vandenberghe; Alberto Lleó; Lutz Frölich; Simon Lovestone; Johannes Streffer; Lars Bertram; Kaj Blennow; Charlotte E Teunissen; Robert Veerhuis; August B Smit; Philip Scheltens; Henrik Zetterberg; Pieter Jelle Visser
Journal:  Alzheimers Res Ther       Date:  2020-05-27       Impact factor: 6.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.